Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots:Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque PsoriasisHe also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2The interview also talks about how BMS is advancing its product portfolio to deliver innovative…